Basel-Landschaft

Switzerland registers first A/H1N1 flu death

GENEVA, Nov. 18 (Xinhua) -- A Swiss baby has died of A/H1N1 influenza, the first fatality from the virus in this country, the official Swissinfo.ch news website reported on Wednesday. The five-month-old baby boy, who died at...

powered by

BASEL, - US Food and Drug Administration grants priority review for Actelion's miglustat in...

ALLSCHWIL/BASEL, SWITZERLAND - 19 November 2009 - Actelion Ltd (SIX: ATLN) announced today that a supplemental new drug application (sNDA) for an extension of indication for Zavesca® (miglustat) for the treatment of progressive...

powered by

Switzerland reports first swine flu death

GENEVA, Nov 18 (AFP) - Switzerland reported its first death from pandemic flu on Wednesday, after a young baby died in the north of the country, Swiss health authorities said. The victim was "an infant in the canton Basel...

powered by

Antares Pharma Enters into License and Asset Purchase Agreements with Ferring

Antares Pharma, Inc. (NYSE Amex: AIS) today announced the simultaneous signing of a license and an asset purchase agreement with Ferring International Center S.A. Under the terms of the exclusive license agreement Ferring...

powered by

Type 2 Diabetes: Findings in type 2 diabetes reported from Actelion Pharmaceuticals Ltd.,...

Fresh data on type 2 diabetes are presented in the report 'Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.' In this recent report,...

powered by

F1-dependent translation of mitochondrially encoded Atp6p and Atp8p subunits of yeast ATP...

Department of Biological Sciences, Columbia University, New York, NY 10027 Communicated by Gottfried Schatz, University of Basel, Reinach, Switzerland, September 11, 2009 (received for review August 6, 2009) Abstract The ATP...

powered by

Dose-finding Phase IIb study started in patients with multiple sclerosis - Actelion/Roche S1P1...

Oct 09, 2009 (Hugin via COMTEX) -- Actelion Ltd (SIX: ATLN) announced today that the selective S1P1 receptor agonist ACT-128800/ RG3477 has achieved an important clinical milestone. Actelion's first-in-class selective S1P1...

powered by

Actelion updates US Healthcare Professionals for patients with type 1 Gaucher disease -...

ALLSCHWIL, SWITZERLAND--(Marketwire - September 8, 2009) - ALLSCHWIL/BASEL, SWITZERLAND - 8 September 2009 - Actelion Ltd (SIX: ATLN) has distributed updated information to Healthcare Professionals who treat type 1 Gaucher...

powered by

Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of...

CAPRA-2-Data Will be Used to File for US Marketing Approval BASEL and REINACH, Switzerland, September 2/PRNewswire/ -- Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the...

powered by

Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of...

BASEL and REINACH, Switzerland, September 2 /PRNewswire/ -- - CAPRA-2-Data Will be Used to File for US Marketing Approval Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the...

powered by
1 2 3 4 next »

               

Subcategories

Liestal , Allschwil